Abstract
Severe lower respiratory illnesses (sLRI) during infancy increase the of asthma. The immunomodulator BronchVaxom® can increase the time to the first sLRI and reduce the cumulative burden of sLRI in at risk infants.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
